Glenmark Pharmaceuticals
- Advice
- Hold
Glenmark Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Glenmark Pharmaceuticals
Start SIPGlenmark Pharmaceuticals Investment Rating
-
Master Rating:
-
Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,990.11 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 7% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 41%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 36% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 1,875 | 2,161 | 2,153 | 1,872 | 1,721 |
| Operating Expenses Qtr Cr | 1,721 | 1,723 | 1,826 | 1,478 | 1,624 |
| Operating Profit Qtr Cr | 218 | 439 | 382 | 434 | 162 |
| Depreciation Qtr Cr | 47 | 46 | 46 | 45 | 42 |
| Interest Qtr Cr | 59 | 56 | 52 | 40 | 74 |
| Tax Qtr Cr | -176 | 159 | 177 | 203 | 19 |
| Net Profit Qtr Cr | -137 | 431 | 423 | 493 | 206 |
Glenmark Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹588.43
- 50 Day
- ₹543.69
- 100 Day
- ₹499.98
- 200 Day
- ₹467.18
- 20 Day
- ₹595.74
- 50 Day
- ₹531.3
- 100 Day
- ₹474.57
- 200 Day
- ₹439.56
Glenmark Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹602.46 |
| Second Resistance | ₹607.15 |
| Third Resistance | ₹612.5 |
| RSI | 66.13 |
| MFI | 47.5 |
| MACD Single Line | 24.62 |
| MACD | 19.95 |
| Support | |
|---|---|
| First Resistance | ₹592.4 |
| Second Resistance | ₹587.05 |
| Third Resistance | ₹582.35 |
Glenmark Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,075,939 | 47,685,616 | 44.32 |
| Week | 909,679 | 46,184,383 | 50.77 |
| 1 Month | 1,906,964 | 83,906,406 | 44 |
| 6 Month | 1,304,840 | 48,696,628 | 37.32 |
Glenmark Pharmaceuticals Result Highlights
Glenmark Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.| Market Cap | 17,201 |
| Sales | 8,221 |
| Shares in Float | 14.95 |
| No of funds | 280 |
| Yield | 0.42 |
| Book Value | 0.94 |
| U/D Vol ratio | 2 |
| LTDebt / Equity | 15 |
| Alpha | 0.13 |
| Beta | 0.89 |
Glenmark Pharmaceuticals
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% |
| Mutual Funds | 5.43% | 5.64% | 6.26% | 5.81% |
| Insurance Companies | 4.41% | 4.48% | 4.16% | |
| Foreign Portfolio Investors | 22.47% | 23.19% | 23.14% | 24.23% |
| Financial Institutions/ Banks | 0.2% | 0.2% | 0.22% | 0.2% |
| Individual Investors | 16.9% | 16.72% | 16.47% | 16.32% |
| Others | 3.94% | 3.12% | 3.1% | 6.79% |
Glenmark Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director - Corporate Affairs |
| Mr. V S Mani | Executive Director & Global CFO |
| Mr. Rajesh V Desai | Non Executive Director |
| Dr. Brian W Tempest | Non Executive Director |
| Mr. Dipankar Bhattacharjee | Non Executive Director |
| Mr. Bernard Munos | Non Executive Director |
| Mr. Sridhar Gorthi | Non Executive Director |
| Mrs. B E Saldanha | Non Executive Director |
| Mr. D R Mehta | Non Executive Director |
| Ms. Saira Ramasastry | Non Executive Director |
Glenmark Pharmaceuticals Forecast
Price Estimates
Glenmark Pharmaceuticals Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-19 | Audited Results & Final Dividend | |
| 2023-02-10 | Quarterly Results | |
| 2022-11-11 | Quarterly Results | |
| 2022-08-10 | Quarterly Results | |
| 2022-05-27 | Audited Results & Final Dividend |
Glenmark Pharmaceuticals FAQs
What is Share Price of Glenmark Pharmaceuticals ?
Glenmark Pharmaceuticals share price is ₹609 As on 01 June, 2023 | 18:18
What is the Market Cap of Glenmark Pharmaceuticals ?
The Market Cap of Glenmark Pharmaceuticals is ₹17201 Cr As on 01 June, 2023 | 18:18
What is the P/E ratio of Glenmark Pharmaceuticals ?
The P/E ratio of Glenmark Pharmaceuticals is 54.5 As on 01 June, 2023 | 18:18
What is the PB ratio of Glenmark Pharmaceuticals ?
The PB ratio of Glenmark Pharmaceuticals is 1.7 As on 01 June, 2023 | 18:18